Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.

Background: Lebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.

Objective: To evaluate the efficacy and safety of lebrikizumab in the treatment of moderate-to-severe AD through a meta-analysis.

Methods: PubMed, Embase, Web of Science, Medline, and ClinicalTrials.

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023.

Tildrakizumab, the IL-23 inhibitor, is used to treat plaque psoriasis and psoriatic arthritis. Many studies have reported adverse drug reactions (ADRs) associated with Tildrakizumab. The aim of this study was to describe ADRs associated with Tildrakizumab monotherapy by mining data from the U.

The top 100 most cited articles in the treatment of basal cell carcinoma over the last decade: A bibliometric analysis and review.

Basal cell carcinoma (BCC) represents the most prevalent cancer globally. The past decade has witnessed significant advancements in BCC treatment, primarily through bibliometric studies. Aiming to perform a comprehensive bibliometric analysis of BCC treatments to comprehend the research landscape and identify trends within this domain, a dataset comprising 100 scientific publications from the Web of Science Core Collection was analyzed.

A Retrospective Analysis of Risk Factors for Atopic Dermatitis Severity.

Atopic dermatitis (AD) has the highest burden of any skin disease; however, the severity-associated factors remain unclear. To evaluate potential severity-associated factors of AD and to design and validate a severity prediction model to inform the management of AD patients. A cross-sectional study of 900 AD patients was conducted from December 2021 to October 2022 at our hospital.